Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain and Modic Type 1 changes PP353 has the potential to ...
In this 2-year follow-up study, we found a significant positive association between the change in the extent of M1 and change in ODI. We also found a positive association between the change in the ...
London, UK, 3 February 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...